PMID- 25702964
OWN - NLM
STAT- MEDLINE
DCOM- 20160309
LR  - 20150324
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 203
DP  - 2015 Apr 10
TI  - Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-kappaB-dependent 
      inflammation process in a mouse model of Parkinson's disease.
PG  - 170-80
LID - S0168-3659(15)00140-6 [pii]
LID - 10.1016/j.jconrel.2015.02.030 [doi]
AB  - Parkinson's disease is a common neurodegenerative disorder of unknown 
      pathogenesis characterized by the loss of nigrostriatal dopaminergic neurons. 
      Oxidative stress, microglial activation and inflammatory responses seem to 
      contribute to the pathogenesis. Recent data showed that growth factors mediate 
      neuroprotection in rodent models of Parkinson's disease, modulating 
      pro-inflammatory processes. Based on our recent studies showing that plasma rich 
      in growth factors (PRGF-Endoret) mediates neuroprotection as inflammatory 
      moderator in Alzheimer's disease, in the present study we examined the effects of 
      plasma rich in growth factors (PRGF-Endoret) in the 
      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse as a 
      translational therapeutic approach for Parkinson's disease. We found substantial 
      neuroprotection by PRGF-Endoret in our model of Parkinson's disease, which 
      resulted in diminished inflammatory responses and improved motor performance. 
      Additionally, these effects were associated with robust reduction in nuclear 
      transcription factor-kappaB (NF-kappaB) activation, and nitric oxide (NO), 
      cyclooxygenase-2 (COX-2), and tumor necrosis factor-alpha (TNF-alpha) expression in 
      the substantia nigra. We propose that PRGF-Endoret can prevent dopaminergic 
      degeneration via an NF-kappaB-dependent signaling process. As the clinical safety 
      profile of PRGF-Endoret is already established, these data suggest that 
      PRGF-Endoret provides a novel neuroprotective strategy for Parkinson's disease.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Anitua, Eduardo
AU  - Anitua E
AD  - Foundation Eduardo Anitua, Vitoria, Spain.
FAU - Pascual, Consuelo
AU  - Pascual C
AD  - Neuroscience Group, Instituto de Investigacion Hospital 12 de Octubre (i+12), 
      Madrid, Spain; Biomedical Research Networking Center in Neurodegenerative 
      Diseases (CIBERNED), Madrid, Spain.
FAU - Perez-Gonzalez, Rocio
AU  - Perez-Gonzalez R
AD  - Neuroscience Group, Instituto de Investigacion Hospital 12 de Octubre (i+12), 
      Madrid, Spain; Biomedical Research Networking Center in Neurodegenerative 
      Diseases (CIBERNED), Madrid, Spain.
FAU - Orive, Gorka
AU  - Orive G
AD  - Foundation Eduardo Anitua, Vitoria, Spain. Electronic address: 
      gorka.orive@bti-implant.es.
FAU - Carro, Eva
AU  - Carro E
AD  - Neuroscience Group, Instituto de Investigacion Hospital 12 de Octubre (i+12), 
      Madrid, Spain; Biomedical Research Networking Center in Neurodegenerative 
      Diseases (CIBERNED), Madrid, Spain. Electronic address: carroeva@h12o.es.
LA  - eng
PT  - Journal Article
DEP - 20150220
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (NF-kappa B)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
SB  - IM
MH  - *1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MH  - Administration, Intranasal
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Disease Models, Animal
MH  - Dopaminergic Neurons/*drug effects/immunology/pathology
MH  - Humans
MH  - Inflammation/*drug therapy/immunology/pathology
MH  - Intercellular Signaling Peptides and Proteins/administration & 
      dosage/*therapeutic use
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/*immunology
MH  - Parkinson Disease, Secondary/*drug therapy/immunology/pathology
MH  - Substantia Nigra/drug effects/immunology/pathology
OTO - NOTNLM
OT  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
OT  - Inflammation
OT  - Neuroprotection
OT  - Parkinson's disease
OT  - Plasma rich in growth factors
EDAT- 2015/02/24 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/02/24 06:00
PHST- 2015/01/29 00:00 [received]
PHST- 2015/02/17 00:00 [revised]
PHST- 2015/02/18 00:00 [accepted]
PHST- 2015/02/24 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2016/03/10 06:00 [medline]
AID - S0168-3659(15)00140-6 [pii]
AID - 10.1016/j.jconrel.2015.02.030 [doi]
PST - ppublish
SO  - J Control Release. 2015 Apr 10;203:170-80. doi: 10.1016/j.jconrel.2015.02.030. 
      Epub 2015 Feb 20.